Responses to Information on Treatments for Depression

Overview

The purpose of this study is to determine the impact of different messages about depression treatments.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Other
    • Masking: None (Open Label)
  • Study Primary Completion Date: November 2020

Detailed Description

Participants recruited through Amazon Mechanical Turk (MTurk) will complete a screening questionnaire and provided the opportunity to consent to participate. Upon entry to the study, eligible participants will complete several questionnaires pre- and post-randomization. Randomization will be to view either a video detailing a type of depression treatment (cognitive behavioral therapy, antidepressant medication, or the combination of both treatments) with and without an emphasis on personalization. A no video condition is also included.

Interventions

  • Other: CBT without Personalization
    • Intervention involves a video describing CBT without a message about personalization.
  • Other: CBT with Personalization
    • Intervention involves a video describing CBT with a message about personalization.
  • Other: ADM without Personalization
    • Intervention involves a video describing antidepressant medication without a message about personalization.
  • Other: ADM with Personalization
    • Intervention involves a video describing antidepressant medication with a message about personalization.
  • Other: Combined Treatment without Personalization
    • Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication without a message about personalization.
  • Other: Combined Treatment with Personalization
    • Intervention involves a video describing the combination of cognitive behavior therapy and antidepressant medication with a message about personalization.

Arms, Groups and Cohorts

  • No Intervention: No video
    • This condition involves no video presentation.
  • Experimental: CBT without Personalization
    • Video provides information about cognitive behavioral therapy.
  • Experimental: CBT with Personalization
    • Video provides information about cognitive behavioral therapy and describes how treatment can be personalized.
  • Experimental: ADM without Personalization
    • Video provides information about antidepressant medications.
  • Experimental: ADM with Personalization
    • Video provides information about antidepressant medications and describes how treatment can be personalized.
  • Experimental: Combined Treatment without Personalization
    • Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications.
  • Experimental: Combined Treatment with Personalization
    • Video provides information on the combined treatment of cognitive behavioral therapy with antidepressant medications and describes how treatment can be personalized.

Clinical Trial Outcome Measures

Primary Measures

  • Regressed change from baseline in expectations on the Credibility/Expectancy Questionnaire (CEQ)
    • Time Frame: Up to 90 minutes to complete assessment. Assessed immediately pre- and post-intervention (on the same day)
    • The CEQ is a validated, commonly used measure assessing views of the credibility and expectations for benefit from a treatment.
  • Regressed change from baseline in prognostic pessimism on an adapted version of the Perceptions of Depression Scale (PDS)
    • Time Frame: Up to 90 minutes to complete assessment. Assessed immediately pre- and post-intervention (on the same day)
    • Measured using an adapted version of the PDS, a validated scale measuring general prognostic pessimism. Minor changes to wording were made to directly address the three different interventions in the study (CBT, ADM, Combined Treatment).

Secondary Measures

  • Regressed change from baseline in affect on the Positive and Negative Affectivity Scale (PANAS)
    • Time Frame: Up to 90 minutes to complete assessment. Assessed immediately pre- and post-intervention (on the same day)
    • The PANAS is a widely used measure for positive and negative affect, and has been shown to be valid and reliable.
  • Regressed Change from baseline on the Beck Hopelessness Scale (BHS)
    • Time Frame: Up to 90 minutes to complete assessment. Assessed immediately pre- and post-intervention (on the same day)
    • The BHS is the most widely used measure for hopelessness, and has been shown to be valid and reliable.
  • Regressed change from baseline in personal and perceived depression stigma on the Depression Stigma Scale (DSS).
    • Time Frame: Up to 90 minutes to complete assessment. Assessed immediately pre- and post-intervention (on the same day)
    • The DSS is a valid and reliable measure for assessing personal and perceived stigma related to depression. The scale contains two subscales: personal stigma and perceived stigma.
  • Regressed change from baseline in beliefs on the etiology of depression on the Reasons for Depression Questionnaire (RFD).
    • Time Frame: Up to 90 minutes to complete assessment. Assessed immediately pre- and post-intervention (on the same day)
    • The RFD is a valid and reliable measure for assessing one’s beliefs on the etiology of depression.
  • Willingness to take a next step.
    • Time Frame: Up to 90 minutes to complete assessment. Assessed at the end of the study questionnaires (same day)
    • Participants are given the option to learn more about finding cognitive behavioral therapy, antidepressant medications, or combination therapy. Based on their responses, they are provided links to relevant websites. This approach has been adopted from traditional marketing research to assess participants’ responsiveness to a message.

Participating in This Clinical Trial

Inclusion Criteria

  • PHQ-9 Score indicating a history of elevated depression symptoms – A high MTurk completion rate – Must pass all attention checks inserted into the questionnaires – No history of treatment for depression Exclusion Criteria:
  • none
  • Gender Eligibility: All

    Minimum Age: 18 Years

    Maximum Age: N/A

    Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

    Investigator Details

    • Lead Sponsor
      • Ohio State University
    • Provider of Information About this Clinical Study
      • Principal Investigator: Daniel R. Strunk, Professor – Ohio State University
    • Overall Official(s)
      • Daniel Strunk, PhD, Principal Investigator, Professor
    • Overall Contact(s)
      • Daniel Strunk, PhD, 614-688-4891, strunk.20@osu.edu

    Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

    At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.